Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

Official Title

A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma

Summary:

The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Trial Description

Primary Outcome:

• Overall Response Rate (ORR)

• Duration of Response
• Overall Survival (OS)
• Progression Free Survival (PFS)
• Disease Control Rate (DCR)
• Prevalence of anti-drug antibodies (ADA) prevalence at baseline
• Incidence of anti-drug antibodies (ADA)
• Percentage of subjects with a favourable biomarker profile (pFBP)

View this trial on ClinicalTrials.gov